Annexon (ANNX)
Develops C1q-targeted therapies for complement-mediated diseases of the body, eye, and brain.
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions225 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 150.85% | 308.41M shares | |
| Insiders9 holders · as of Jun 15, 2026 | 6.05% | 12.36M shares | |
| Adds to | 156.90% |
204.44M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (204.44M in the company's Sep 3, 2026 report, 163.84M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 156.90%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Institutions13F, as of Mar 31, 2026
225 holders · 154.21M shares · 66 new positions · 154 increased · 48 reduced · 17 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Redmile Group, LLC | 14.55M | 7.12% | +4.50M | May 15, 2026 |
| BlackRock, Inc. | 10.94M | 5.35% | +1.98M | May 13, 2026 |
| FMR LLC | 10.64M | 5.20% | +413.2K | May 15, 2026 |
| BVF Inc/IL | 8.70M | 4.25% | −429.9K | May 15, 2026 |
| State Street Corp | 6.92M | 3.38% | +2.27M | May 15, 2026 |
| Vanguard Capital Management LLC | 5.96M | 2.91% | +5.96Mnew | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | 5.21M | 2.55% | −36.4K | May 15, 2026 |
| Bellevue Group AG | 5.16M | 2.52% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Logos GP LLCincl. Logos Global Management LP, Logos Global Management GP LLC +2 more | 11.00% | 2.90M | 13G/A | Nov 14, 2024 ↗ |
| Redmile Group, LLC | 9.90% | 15.43M | 13G | Feb 17, 2026 ↗ |
| Satter Muneer A | 7.20% | 10.44M | 13D | Nov 21, 2025 ↗ |
| FMR LLC | 7.10% | 10.22M | 13G | Feb 5, 2026 ↗ |
| BlackRock, Inc. | 6.10% | 8.87M | 13G | Jan 21, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 28, 2026 | Muneer A. Satterdirector | Purchase | 613,497 | $5.41 | 10,342,134 |
| May 11, 2026 | William H. Carsondirector | Purchase | 8,000 | $5.78 | 78,405 |
| Apr 10, 2026 | William H. Carsondirector | Purchase | 8,000 | $6.20 | 70,405 |
| Mar 10, 2026 | William H. Carsondirector | Purchase | 8,000 | $5.67 | 62,405 |
| Mar 2, 2026 | Jennifer Lewofficer: EVP & CHIEF FINANCIAL OFFICER | Sale | 5,565 | $5.42 | 170,700 |
| Mar 2, 2026 | Dean Richard Artisofficer: EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,894 | $5.43 | 180,093 |
| Mar 2, 2026 | Ted Yednockofficer: EVP & CHIEF INNOVATION OFFICER | Sale | 5,566 | $5.42 | 154,161 |
| Mar 2, 2026 | Michael Overdorfofficer: EVP & CHIEF BUSINESS OFFICER | Sale | 4,339 | $5.42 | 182,625 |
| Mar 2, 2026 | Jamie Dananbergofficer: CHIEF MEDICAL OFFICER | Sale | 5,820 | $5.43 | 123,582 |
| Feb 18, 2026 | Michael Overdorfofficer: EVP & CHIEF BUSINESS OFFICER | Sale | 6,225 | $5.10 | 124,464 |
CongressHouse and Senate disclosures
Not reported.